{"items": "85", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug", "url": "https://www.zacks.com/stock/news/2382224/qure-soars-on-fda-alignment-for-speedy-approval-of-huntingtons-drug", "time_published": "20241211T150200", "authors": ["Zacks Equity Research"], "summary": "uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221514, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.211191", "ticker_sentiment_score": "0.066085", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.211191", "ticker_sentiment_score": "0.274281", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.211191", "ticker_sentiment_score": "0.125651", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.127682", "ticker_sentiment_score": "0.086009", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More", "url": "https://www.zacks.com/stock/news/2382213/biotech-stock-roundup-bioa-down-on-study-update-qure-crdf-gain-on-study-data-more", "time_published": "20241211T145500", "authors": ["Zacks Equity Research"], "summary": "It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.192489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.040145", "ticker_sentiment_score": "0.196007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.19871", "ticker_sentiment_score": "0.26053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QURE", "relevance_score": "0.12003", "ticker_sentiment_score": "0.257279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIOA", "relevance_score": "0.12003", "ticker_sentiment_score": "-0.099555", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRDF", "relevance_score": "0.19871", "ticker_sentiment_score": "0.077938", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.080188", "ticker_sentiment_score": "0.060458", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2024/12/10/2994386/0/en/uniQure-Announces-Alignment-with-FDA-on-Key-Elements-of-Accelerated-Approval-Pathway-for-AMT-130-in-Huntington-s-Disease.html", "time_published": "20241210T120500", "authors": ["uniQure Inc."], "summary": "~ U.S. Food and Drug Administration ( FDA ) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application ( BLA ) for Accelerated Approval ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.139962, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.048621", "ticker_sentiment_score": "0.120782", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy", "url": "https://www.globenewswire.com/news-release/2024/11/21/2985098/0/en/uniQure-Announces-Dosing-of-First-Patient-in-GenTLE-Phase-I-IIa-Clinical-Trial-of-AMT-260-for-the-Treatment-of-Refractory-Mesial-Temporal-Lobe-Epilepsy.html", "time_published": "20241121T120500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.092365, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.085936", "ticker_sentiment_score": "0.091577", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2024/11/05/2974805/0/en/uniQure-Announces-Third-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20241105T120500", "authors": ["uniQure Inc."], "summary": "~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.138536, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.032425", "ticker_sentiment_score": "0.043202", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS", "url": "https://www.globenewswire.com/news-release/2024/10/15/2963063/0/en/uniQure-Announces-Dosing-of-First-Patient-in-Phase-I-II-Clinical-Trial-of-AMT-162-for-the-Treatment-SOD1-ALS.html", "time_published": "20241015T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.048082, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.076358", "ticker_sentiment_score": "0.092449", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease", "url": "https://www.globenewswire.com/news-release/2024/09/23/2951251/0/en/uniQure-Announces-Orphan-Drug-Designation-Granted-to-AMT-191-for-the-Treatment-of-Fabry-Disease.html", "time_published": "20240923T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S.", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.159209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.078226", "ticker_sentiment_score": "0.028674", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.03916", "ticker_sentiment_score": "0.15702", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology", "url": "https://www.benzinga.com/pressreleases/24/09/g40833623/gene-therapy-market-set-for-19-cagr-surge-reaching-usd-38-34-billion-by-2031-skyquest-technology", "time_published": "20240912T133000", "authors": ["Globe Newswire"], "summary": "Westford, USA, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period ( 2024-2031 ) .", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.230526, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRYS", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.039878", "ticker_sentiment_score": "0.026899", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease", "url": "https://www.globenewswire.com/news-release/2024/08/15/2930804/0/en/uniQure-Announces-Dosing-of-First-Patient-in-Phase-I-IIa-Clinical-Trial-of-AMT-191-for-the-Treatment-of-Fabry-Disease.html", "time_published": "20240815T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.176794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.072435", "ticker_sentiment_score": "0.082865", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.036255", "ticker_sentiment_score": "0.158973", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update", "url": "https://www.globenewswire.com/news-release/2024/08/01/2922648/0/en/uniQure-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Company-Update.html", "time_published": "20240801T110500", "authors": ["uniQure Inc."], "summary": "~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration. Meeting with FDA expected in the second half of 2024 to discuss potential for expedited ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.184782, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.033144", "ticker_sentiment_score": "0.04332", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Closing of Sale of Manufacturing Facility to Genezen", "url": "https://www.globenewswire.com/news-release/2024/07/23/2917097/0/en/uniQure-Announces-Closing-of-Sale-of-Manufacturing-Facility-to-Genezen.html", "time_published": "20240723T110500", "authors": ["uniQure Inc."], "summary": "~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.139971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.023246", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure", "url": "https://www.zacks.com/stock/news/2300042/biotech-stock-roundup-kymr-idya-qure-soar-on-study-data-hlvx-tanks-on-study-failure", "time_published": "20240711T131200", "authors": ["Zacks Equity Research"], "summary": "IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.071901, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.156207", "ticker_sentiment_score": "0.15601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IDYA", "relevance_score": "0.117486", "ticker_sentiment_score": "0.07438", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.078482", "ticker_sentiment_score": "0.125886", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLVX", "relevance_score": "0.194554", "ticker_sentiment_score": "-0.246688", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.156207", "ticker_sentiment_score": "0.15601", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "UniQure Soars on New Huntington's Disease Study Data", "url": "https://markets.businessinsider.com/news/stocks/uniqure-soars-on-new-huntington-s-disease-study-data-1033544723", "time_published": "20240710T205623", "authors": ["Zacks"], "summary": "uniQure N.V. ( NASDAQ:QURE ) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 29 treated patients enrolled in the ongoing early to mid-stage studies of AMT-130 for Huntington's disease in the United States and EU. Results ...", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/10/national-cancer-institute-uxnbyoejxce-unsplash.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.107619, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.081276", "ticker_sentiment_score": "0.054774", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.081276", "ticker_sentiment_score": "0.028953", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.063214", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.050108", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( QURE )  Soars on New Huntington's Disease Study Data", "url": "https://www.zacks.com/stock/news/2299274/uniqure-qure-soars-on-new-huntingtons-disease-study-data", "time_published": "20240710T130100", "authors": ["Zacks Equity Research"], "summary": "uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.109802, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.117486", "ticker_sentiment_score": "0.05768", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.053815", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.156207", "ticker_sentiment_score": "-0.023304", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.156207", "ticker_sentiment_score": "-0.010969", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2024/07/09/2910220/0/en/uniQure-Announces-Positive-Interim-Data-Update-Demonstrating-Slowing-of-Disease-Progression-in-Phase-I-II-Trials-of-AMT-130-for-Huntington-s-Disease.html", "time_published": "20240709T110500", "authors": ["uniQure Inc."], "summary": "~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit. Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale ( cUHDRS ) at 24 months compared to a propensity ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.120605, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.03387", "ticker_sentiment_score": "-0.008544", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Sale of Commercial Manufacturing Facility to Genezen", "url": "https://www.globenewswire.com/news-release/2024/07/01/2906599/0/en/uniQure-Announces-Sale-of-Commercial-Manufacturing-Facility-to-Genezen.html", "time_published": "20240701T110500", "authors": ["uniQure Inc."], "summary": "~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.147139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.064104", "ticker_sentiment_score": "0.021135", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Receives FDA Regenerative Medicine Advanced Therapy  ( RMAT )  Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2024/06/03/2892124/0/en/uniQure-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-Investigational-Gene-Therapy-AMT-130-in-Huntington-s-Disease.html", "time_published": "20240603T110500", "authors": ["uniQure Inc."], "summary": "~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.111545, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.054794", "ticker_sentiment_score": "0.055999", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2024/05/07/2876578/0/en/uniQure-Announces-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20240507T110500", "authors": ["uniQure Inc."], "summary": "uniQure announces first quarter 2024 results ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.1749, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044885", "ticker_sentiment_score": "0.044682", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Upgraded to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2024/03/03/uniqure-nasdaqqure-upgraded-to-sell-at-stocknews-com.html", "time_published": "20240303T074844", "authors": ["Defense World Staff"], "summary": "uniQure ( NASDAQ:QURE - Get Free Report ) was upgraded by StockNews.com to a \"sell\" rating in a note issued to investors on Friday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}], "overall_sentiment_score": 0.222525, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.098862", "ticker_sentiment_score": "0.159936", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QURE", "relevance_score": "0.098862", "ticker_sentiment_score": "0.019384", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.098862", "ticker_sentiment_score": "0.159936", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.007955", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.007955", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.098862", "ticker_sentiment_score": "0.159936", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.049526", "ticker_sentiment_score": "0.042955", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces 2023 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2024/02/28/2836825/0/en/uniQure-Announces-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20240228T120500", "authors": ["uniQure Inc."], "summary": "~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease. Up to three years of follow-up data to be presented in mid-2024. Regulatory interactions and clarity on potential strategies for clinical development expected in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.19138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.043264", "ticker_sentiment_score": "0.042552", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2023/12/19/2798425/0/en/uniQure-Announces-Update-on-Phase-I-II-Clinical-Trials-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html", "time_published": "20231219T120500", "authors": ["uniQure Inc."], "summary": "~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.035938, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.03072", "ticker_sentiment_score": "-0.009359", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/12/08/2793129/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20231208T120500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.240917, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.24289", "ticker_sentiment_score": "0.207303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease", "url": "https://www.globenewswire.com/news-release/2023/11/29/2787620/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-191-Gene-Therapy-for-Fabry-Disease.html", "time_published": "20231129T120500", "authors": ["uniQure Inc."], "summary": "Patient enrollment expected to begin in first half of 2024 Patient enrollment expected to begin in first half of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.131364, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.097259", "ticker_sentiment_score": "0.076751", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.097259", "ticker_sentiment_score": "0.16076", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/11/07/2774943/0/en/uniQure-Announces-Third-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20231107T120500", "authors": ["uniQure Inc."], "summary": "~ Announced FDA clearance of Investigational New Drug ( IND ) application for AMT-260 in refractory mesial temporal lobe epilepsy ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.237638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.043499", "ticker_sentiment_score": "0.044577", "ticker_sentiment_label": "Neutral"}]}, {"title": "CSL and uniQure Win 2023 Prix Galien USA Award", "url": "https://www.prnewswire.com/news-releases/csl-and-uniqure-win-2023-prix-galien-usa-award-301970222.html", "time_published": "20231027T140000", "authors": ["CSL"], "summary": "HEMGENIX\u00ae, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases", "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/common/newsletter-signup.png", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002437, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.063933", "ticker_sentiment_score": "0.124601", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Major Presence at the European Society of Gene and Cell Therapy  ( ESGCT )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2023/10/24/2765472/0/en/uniQure-Announces-Major-Presence-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-Annual-Meeting.html", "time_published": "20231024T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.053969, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.100518", "ticker_sentiment_score": "-0.010731", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback", "url": "https://www.zacks.com/stock/news/2164807/biotech-stock-roundup-bmy-grabs-mrtx-akro-down-on-study-data-alny-faces-setback", "time_published": "20231012T122400", "authors": ["Ekta Bagri"], "summary": "Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.104407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.134402", "ticker_sentiment_score": "0.063039", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKRO", "relevance_score": "0.101012", "ticker_sentiment_score": "0.039293", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.067441", "ticker_sentiment_score": "-0.02003", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.033751", "ticker_sentiment_score": "0.092178", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.101012", "ticker_sentiment_score": "0.064655", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033751", "ticker_sentiment_score": "0.032519", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( QURE )  Up on Restructuring Plans, Workforce Reduction", "url": "https://www.zacks.com/stock/news/2161746/uniqure-qure-up-on-restructuring-plans-workforce-reduction", "time_published": "20231006T153100", "authors": ["Zacks Equity Research"], "summary": "uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.075085, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.153961", "ticker_sentiment_score": "0.079756", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.302243", "ticker_sentiment_score": "-0.090642", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETON", "relevance_score": "0.153961", "ticker_sentiment_score": "0.079756", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs", "url": "https://www.globenewswire.com/news-release/2023/10/05/2755260/0/en/uniQure-Announces-Strategic-Reorganization-to-Reduce-Operating-Expenses-and-Support-Advancement-of-Multiple-Clinical-Stage-Programs.html", "time_published": "20231005T110500", "authors": ["uniQure Inc."], "summary": "~ Reduction of 28% of workforce not related to HEMGENIX\u00ae manufacturing obligations. Total cost savings of $180 million to extend cash runway into second quarter of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.199992, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.051496", "ticker_sentiment_score": "0.08896", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/10/02/2752634/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20231002T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.236334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.241684", "ticker_sentiment_score": "0.206503", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy", "url": "https://www.globenewswire.com/news-release/2023/09/05/2737179/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-260-Gene-Therapy-for-Refractory-Mesial-Temporal-Lobe-Epilepsy.html", "time_published": "20230905T110500", "authors": ["uniQure Inc."], "summary": "Clinical trial initiation expected in the fourth quarter of 2023 Clinical trial initiation expected in the fourth quarter of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016736, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.043854", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600", "url": "https://markets.businessinsider.com/news/stocks/blackstone-and-airbnb-set-to-join-s-p-500-others-to-join-s-p-100-s-p-midcap-400-and-s-p-smallcap-600-1032600818", "time_published": "20230901T225100", "authors": ["markets.businessinsider.com"], "summary": "Blackstone and Airbnb Set to Join S&P 500. Others to Join S&P 100, S&P MidCap 400 and ...", "banner_image": "https://c212.net/c/img/favicon.png?sn=CL99371&sd=2023-09-01", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.113564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LNC", "relevance_score": "0.114137", "ticker_sentiment_score": "0.124401", "ticker_sentiment_label": "Neutral"}, {"ticker": "DE", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.065943", "ticker_sentiment_label": "Neutral"}, {"ticker": "PR", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRIP", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPI", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.057215", "ticker_sentiment_score": "0.111956", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGHT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "SXT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIK", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBC", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.090947", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDDY", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "PZZA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMAX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTGR", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "LBRT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPSI", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWL", "relevance_score": "0.114137", "ticker_sentiment_score": "0.124401", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "HASI", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAWEL", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.100949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VST", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPI", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "FF", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "UVE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.111956", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENR", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINC", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONL", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.114137", "ticker_sentiment_score": "0.088685", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.170475", "ticker_sentiment_score": "-0.090766", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.114137", "ticker_sentiment_score": "0.207323", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZYXI", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "ST", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXMT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMCL", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLY", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.111956", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENTA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIW", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "CATY", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}, {"ticker": "HE", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.100949", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNF", "relevance_score": "0.057215", "ticker_sentiment_score": "0.030957", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Downgrades uniQure  ( NASDAQ:QURE )  to Sell", "url": "https://www.defenseworld.net/2023/08/08/stocknews-com-downgrades-uniqure-nasdaqqure-to-sell.html", "time_published": "20230808T091044", "authors": ["Defense World Staff"], "summary": "uniQure ( NASDAQ:QURE - Get Free Report ) was downgraded by analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a research note issued to investors on Tuesday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.247601, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.042122", "ticker_sentiment_score": "0.026354", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.084127", "ticker_sentiment_score": "0.196673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QURE", "relevance_score": "0.084127", "ticker_sentiment_score": "0.037204", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.084127", "ticker_sentiment_score": "0.196673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.042122", "ticker_sentiment_score": "0.026354", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/08/02/uniqure-nasdaqqure-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20230802T063242", "authors": ["Defense World Staff"], "summary": "uniQure ( NASDAQ:QURE - Get Free Report ) was upgraded by analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued to investors on Monday. A number of other equities research analysts also recently weighed in on the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.803643"}], "overall_sentiment_score": 0.233219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.097655", "ticker_sentiment_score": "0.234656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.048919", "ticker_sentiment_score": "0.022887", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.146025", "ticker_sentiment_score": "0.128387", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.097655", "ticker_sentiment_score": "0.234656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.048919", "ticker_sentiment_score": "0.022887", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.097655", "ticker_sentiment_score": "0.234656", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/08/01/2715661/0/en/uniQure-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20230801T110500", "authors": ["uniQure Inc."], "summary": "~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease showing preservation of function compared to baseline and clinical benefits relative to natural history. both dose cohorts of AMT-130 continue to be generally ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.145208, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.032602", "ticker_sentiment_score": "0.043231", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.016304", "ticker_sentiment_score": "0.049953", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.032602", "ticker_sentiment_score": "0.05496", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.016304", "ticker_sentiment_score": "0.049953", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.016304", "ticker_sentiment_score": "0.049953", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Lowers uniQure  ( NASDAQ:QURE )  to Sell", "url": "https://www.defenseworld.net/2023/07/20/stocknews-com-lowers-uniqure-nasdaqqure-to-sell.html", "time_published": "20230720T052248", "authors": ["Defense World Staff"], "summary": "uniQure ( NASDAQ:QURE - Get Free Report ) was downgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"sell\" rating in a research note issued to investors on Thursday. Several other analysts have also issued reports on the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.197959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.049019", "ticker_sentiment_score": "0.01393", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.049019", "ticker_sentiment_score": "0.018992", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPLA", "relevance_score": "0.049019", "ticker_sentiment_score": "0.205369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.049019", "ticker_sentiment_score": "0.000992", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.049019", "ticker_sentiment_score": "0.018992", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.049019", "ticker_sentiment_score": "0.01393", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/07/09/uniqure-nasdaqqure-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230709T054241", "authors": ["Defense World Staff"], "summary": "uniQure ( NASDAQ:QURE - Free Report ) was downgraded by equities research analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a report released on Friday. Several other equities research analysts have also recently commented on the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.199443, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.049526", "ticker_sentiment_score": "0.013821", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.096941", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.049526", "ticker_sentiment_score": "0.000993", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.098862", "ticker_sentiment_score": "0.175201", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSBC", "relevance_score": "0.049526", "ticker_sentiment_score": "0.163412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.049526", "ticker_sentiment_score": "0.031989", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Downgraded to Sell at StockNews.com", "url": "https://www.defenseworld.net/2023/07/08/uniqure-nasdaqqure-downgraded-to-sell-at-stocknews-com.html", "time_published": "20230708T081641", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of uniQure ( NASDAQ:QURE - Free Report ) from a hold rating to a sell rating in a report published on Friday. A number of other equities research analysts have also recently commented on QURE. Guggenheim dropped their target price on uniQure from $53.00 to $46.00 in ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.218349, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.044801", "ticker_sentiment_score": "0.008851", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.089462", "ticker_sentiment_score": "0.02309", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.089462", "ticker_sentiment_score": "0.173288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.044801", "ticker_sentiment_score": "0.008851", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.089462", "ticker_sentiment_score": "0.173288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.044801", "ticker_sentiment_score": "0.031872", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAMG", "relevance_score": "0.089462", "ticker_sentiment_score": "0.173288", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Leadership Addition to Support Advancement of Clinical Programs", "url": "https://www.globenewswire.com/news-release/2023/06/26/2694317/0/en/uniQure-Announces-Leadership-Addition-to-Support-Advancement-of-Clinical-Programs.html", "time_published": "20230626T111100", "authors": ["uniQure Inc."], "summary": "~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~ ~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.159749, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.072987", "ticker_sentiment_score": "0.07789", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.036532", "ticker_sentiment_score": "0.025962", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.109289", "ticker_sentiment_score": "0.029768", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036532", "ticker_sentiment_score": "0.025962", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( QURE )  Falls on Mixed Huntington's Disease Study Results", "url": "https://www.zacks.com/stock/news/2111826/uniqure-qure-falls-on-mixed-huntingtons-disease-study-results", "time_published": "20230622T141700", "authors": ["Zacks Investment Research"], "summary": "uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.08329, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADMA", "relevance_score": "0.239541", "ticker_sentiment_score": "0.165704", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AKRO", "relevance_score": "0.285526", "ticker_sentiment_score": "0.114408", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.239541", "ticker_sentiment_score": "-0.067882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.285526", "ticker_sentiment_score": "0.072191", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2023/06/21/2691872/0/en/uniQure-Announces-Update-on-U-S-Phase-I-II-Clinical-Trial-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html", "time_published": "20230621T110500", "authors": ["uniQure Inc."], "summary": "~ AMT-130 continues to be generally well-tolerated across both dose cohorts ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b4b22dda-4970-4ea5-bf8e-07bfb2b1faca", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.095222, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.032425", "ticker_sentiment_score": "0.031437", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTBLF", "relevance_score": "0.016216", "ticker_sentiment_score": "0.08808", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy", "url": "https://www.globenewswire.com/news-release/2023/06/20/2690928/0/en/uniQure-announces-achievement-of-100-million-milestone-related-to-hemophilia-B-gene-therapy.html", "time_published": "20230620T110500", "authors": ["uniQure Inc."], "summary": "Milestone payment triggered by first commercial sale of HEMGENIX\u00ae in U.S. by CSL Behring Milestone payment triggered by first commercial sale of HEMGENIX\u00ae in U.S. by CSL Behring ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.065264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.056143", "ticker_sentiment_score": "-0.036051", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/06/16/2689651/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20230616T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to Jeannette Potts, the Company's ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.269965, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.178459", "ticker_sentiment_score": "0.16282", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Sale of Royalty Interest in HEMGENIX\u00ae for Up To $400 Million", "url": "https://www.globenewswire.com/news-release/2023/05/15/2668613/0/en/uniQure-Announces-Sale-of-Royalty-Interest-in-HEMGENIX-for-Up-To-400-Million.html", "time_published": "20230515T110500", "authors": ["uniQure Inc."], "summary": "~ uniQure to receive $375 million upfront cash payment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.215376, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.057559", "ticker_sentiment_score": "-0.005003", "ticker_sentiment_label": "Neutral"}, {"ticker": "MC", "relevance_score": "0.028798", "ticker_sentiment_score": "0.067215", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/05/09/2664265/0/en/uniQure-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20230509T110500", "authors": ["uniQure Inc."], "summary": "~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.105845, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.042159", "ticker_sentiment_score": "0.042457", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2023/05/02/2659829/0/en/uniQure-Announces-Major-Presence-at-Upcoming-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html", "time_published": "20230502T204000", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061518, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.093289", "ticker_sentiment_score": "-0.010515", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/05/02/2658987/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20230502T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 38 employees as a material ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.32239, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.295867", "ticker_sentiment_score": "0.331448", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/03/13/2625574/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20230313T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.237728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.252987", "ticker_sentiment_score": "0.289352", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs - bluebird bio  ( NASDAQ:BLUE ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31300483/hefty-listing-price-of-new-drugs-for-cancer-rare-diseases-put-pressure-on-annual-hike-for-older-d", "time_published": "20230310T181042", "authors": ["Vandana Singh"], "summary": "New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's ( NASDAQ: AMGN ) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/10/pills-_image_by_thomas_breher_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038479, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.210274", "ticker_sentiment_score": "0.013086", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.310843", "ticker_sentiment_score": "-0.149909", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.210274", "ticker_sentiment_score": "-0.187033", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "uniQure to Participate in Multiple Upcoming Industry Conferences in March", "url": "https://www.globenewswire.com/news-release/2023/03/02/2619154/0/en/uniQure-to-Participate-in-Multiple-Upcoming-Industry-Conferences-in-March.html", "time_published": "20230302T120500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.023494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.139669", "ticker_sentiment_score": "0.018452", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces 2022 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2023/02/27/2615948/0/en/uniQure-Announces-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20230227T120500", "authors": ["uniQure Inc."], "summary": "~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.140672, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HTGC", "relevance_score": "0.018684", "ticker_sentiment_score": "0.151454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QURE", "relevance_score": "0.037358", "ticker_sentiment_score": "0.045929", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX\u00ae  ( etranacogene dezaparvovec-drlb ) ", "url": "https://www.globenewswire.com/news-release/2023/02/23/2614293/0/en/uniQure-Announces-HOPE-B-Clinical-Trial-Data-Published-in-the-New-England-Journal-of-Medicine-Demonstrating-Durability-and-Other-Benefits-of-HEMGENIX-etranacogene-dezaparvovec-drlb.html", "time_published": "20230223T130500", "authors": ["uniQure Inc."], "summary": "~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.04114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.04028", "ticker_sentiment_score": "-0.040584", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B", "url": "https://www.globenewswire.com/news-release/2023/02/21/2611969/0/en/uniQure-announces-the-European-Commission-approval-of-the-first-gene-therapy-for-adults-with-hemophilia-B.html", "time_published": "20230221T120500", "authors": ["uniQure Inc."], "summary": "~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.031589, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.040587", "ticker_sentiment_score": "-0.110937", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2022/12/20/2576954/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20221220T120500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.283877, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.215894", "ticker_sentiment_score": "0.223646", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EU regulator backs gene therapy to treat rare bleeding disorder", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-gene-therapy-treat-rare-bleeding-disorder-2022-12-16/", "time_published": "20221216T121800", "authors": ["Reuters"], "summary": "Dec 16 ( Reuters ) - The European Union's health regulator on Friday said it had recommended granting a conditional marketing authorisation for a gene therapy by Australian drugmaker CSL Ltd ( CSL.AX ) and partner uniQure N.V. , to treat haemophilia B, a rare bleeding disorder which is caused by ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.png?d=124", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016893, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMXHF", "relevance_score": "0.380012", "ticker_sentiment_score": "-0.029838", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.380012", "ticker_sentiment_score": "0.146509", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure announces positive CHMP opinion for etranacogene dezaparvovec - gene therapy for adults with hemophilia B", "url": "https://www.globenewswire.com/news-release/2022/12/16/2575374/0/en/uniQure-announces-positive-CHMP-opinion-for-etranacogene-dezaparvovec-gene-therapy-for-adults-with-hemophilia-B.html", "time_published": "20221216T121500", "authors": ["uniQure Inc."], "summary": "If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004845, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.055751", "ticker_sentiment_score": "0.033006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.027892", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy  ( rTLE )  at Virtual Research & Development Event", "url": "https://www.globenewswire.com/news-release/2022/11/29/2564284/0/en/uniQure-Highlights-Therapeutic-Potential-of-AMT-260-in-Refractory-Temporal-Lobe-Epilepsy-rTLE-at-Virtual-Research-Development-Event.html", "time_published": "20221129T160000", "authors": ["uniQure Inc."], "summary": "~ IND Submission and Clinical Development Expected to Begin in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178107, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.067347", "ticker_sentiment_score": "0.108426", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure announces FDA approval of first gene therapy for adults with hemophilia B", "url": "https://www.globenewswire.com/news-release/2022/11/22/2561267/0/en/uniQure-announces-FDA-approval-of-first-gene-therapy-for-adults-with-hemophilia-B.html", "time_published": "20221122T214000", "authors": ["uniQure Inc."], "summary": "~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/77d555b1-6d49-48f7-8f99-67954a7a9e69", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.033375", "ticker_sentiment_score": "-0.002888", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022", "url": "https://www.globenewswire.com/news-release/2022/11/17/2558039/0/en/uniQure-to-Host-Virtual-Research-Development-Event-on-Tuesday-November-29-2022.html", "time_published": "20221117T120500", "authors": ["uniQure Inc."], "summary": "~ Event to be Webcast Live on uniQure's Corporate Website at 8:30 a.m. EST ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.076799, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.282234", "ticker_sentiment_score": "-0.022928", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2022/11/02/2546342/0/en/uniQure-Announces-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20221102T110500", "authors": ["uniQure Inc."], "summary": "~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation ~~ U.S. and European pre-approval inspections of Company's Lexington, MA manufacturing site completed with EMA issuing Good Manufacturing Certificate ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.157315, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTGC", "relevance_score": "0.021256", "ticker_sentiment_score": "0.205501", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QURE", "relevance_score": "0.042496", "ticker_sentiment_score": "0.044492", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy  ( ESGCT ) ", "url": "https://www.globenewswire.com/news-release/2022/10/11/2531670/0/en/uniQure-Announces-Multiple-Presentations-at-the-Upcoming-Annual-Meeting-of-The-European-Society-of-Gene-and-Cell-Therapy-ESGCT.html", "time_published": "20221011T110500", "authors": ["uniQure Inc."], "summary": "Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.152883, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.150122", "ticker_sentiment_score": "-0.012875", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure to Participate in Upcoming Industry Conferences in October", "url": "https://www.globenewswire.com/news-release/2022/10/03/2526678/0/en/uniQure-to-Participate-in-Upcoming-Industry-Conferences-in-October.html", "time_published": "20221003T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.039562, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.2872", "ticker_sentiment_score": "-0.00622", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure to Participate in Upcoming Industry Conferences in September", "url": "https://www.globenewswire.com/news-release/2022/09/06/2510230/0/en/uniQure-to-Participate-in-Upcoming-Industry-Conferences-in-September.html", "time_published": "20220906T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.044185, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.166743", "ticker_sentiment_score": "0.013605", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.083833", "ticker_sentiment_score": "0.010233", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Downgraded by StockNews.com to Sell", "url": "https://reporter.am/2022/08/14/uniqure-nasdaqqure-downgraded-by-stocknews-com-to-sell.html", "time_published": "20220814T095455", "authors": ["AM Reporter Staff"], "summary": "StockNews.com cut shares of uniQure ( NASDAQ:QURE - Get Rating ) from a hold rating to a sell rating in a report released on Wednesday morning. A number of other equities analysts also recently issued reports on the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "reporter.am", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.189154, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.048133", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.190793", "ticker_sentiment_score": "0.086539", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.048133", "ticker_sentiment_score": "-0.038883", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.096091", "ticker_sentiment_score": "0.194929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.048133", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.048133", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "JACK", "relevance_score": "0.048133", "ticker_sentiment_score": "-0.038883", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Downgraded by StockNews.com", "url": "https://www.defenseworld.net/2022/08/12/uniqure-nasdaqqure-downgraded-by-stocknews-com.html", "time_published": "20220812T060442", "authors": ["admin"], "summary": "uniQure ( NASDAQ:QURE - Get Rating ) was downgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Wednesday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.846708"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.230917, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.048327", "ticker_sentiment_score": "0.056287", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.191549", "ticker_sentiment_score": "0.141492", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.096477", "ticker_sentiment_score": "0.215792", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.048327", "ticker_sentiment_score": "0.056287", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.048327", "ticker_sentiment_score": "0.056287", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Rating Lowered to Sell at StockNews.com", "url": "https://www.etfdailynews.com/2022/08/12/uniqure-nasdaqqure-rating-lowered-to-sell-at-stocknews-com/", "time_published": "20220812T060442", "authors": ["MarketBeat News"], "summary": "uniQure ( NASDAQ:QURE - Get Rating ) was downgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Wednesday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.etfdailynews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.1713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.04823", "ticker_sentiment_score": "0.023857", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.19117", "ticker_sentiment_score": "0.0727", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.04823", "ticker_sentiment_score": "0.023857", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.096283", "ticker_sentiment_score": "0.145748", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.04823", "ticker_sentiment_score": "0.023857", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why uniQure Stock Is Crashing Today", "url": "https://www.fool.com/investing/2022/08/08/why-uniqure-stock-is-crashing-today/", "time_published": "20220808T155350", "authors": ["Keith Speights"], "summary": "The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.", "banner_image": "https://g.foolcdn.com/editorial/images/686535/neurologist-shows-patient-a-brain-scan-image.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.198862, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.288893", "ticker_sentiment_score": "-0.391619", "ticker_sentiment_label": "Bearish"}]}, {"title": "uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2022/08/08/2493736/0/en/uniQure-Announces-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20220808T110500", "authors": ["uniQure Inc."], "summary": "~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein ( mHTT ) observed in cerebral spinal fluid ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.080398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.036228", "ticker_sentiment_score": "0.043781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%", "url": "https://www.investors.com/news/technology/stock-upgrades-uniqure-n-v-shows-rising-relative-strength-3/", "time_published": "20220711T223000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY", "JAMES DETAR"], "summary": "Uniqure Stock Ranks Among Top 8% Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.200932, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.172097", "ticker_sentiment_score": "0.080245", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.172097", "ticker_sentiment_score": "0.080245", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.207572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMPH", "relevance_score": "0.172097", "ticker_sentiment_score": "0.080245", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( QURE )  Up on Safety Data From Huntington's Disease Study", "url": "https://www.zacks.com/stock/news/1943610/uniqure-qure-up-on-safety-data-from-huntingtons-disease-study", "time_published": "20220624T143000", "authors": ["Zacks Investment Research"], "summary": "uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.001283, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AGLE", "relevance_score": "0.342803", "ticker_sentiment_score": "0.012767", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.140896", "ticker_sentiment_score": "0.033266", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.342803", "ticker_sentiment_score": "0.007369", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPTX", "relevance_score": "0.342803", "ticker_sentiment_score": "0.006147", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why UniQure Shares Are Trading Higher Today", "url": "https://www.benzinga.com/general/biotech/22/06/27830566/uniqure-shares-are-up-after-low-dose-cohort-data-from-huntingtons-gene-therapy-trial", "time_published": "20220623T180522", "authors": ["Vandana Singh"], "summary": "UniQure N.V. QURE announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease. Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/23/aapharma_8.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.047231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.524949", "ticker_sentiment_score": "0.021764", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2022/06/23/2467860/0/en/uniQure-Announces-Update-on-Low-Dose-Cohort-in-Phase-I-II-Clinical-Trial-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html", "time_published": "20220623T110500", "authors": ["uniQure Inc."], "summary": "~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/154d56ac-df99-4569-b473-f1f9fc2207b9?size=2", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019795, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.041527", "ticker_sentiment_score": "0.019795", "ticker_sentiment_label": "Neutral"}]}, {"title": "CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2022/06/22/2467524/0/en/CORRECTION-uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20220622T203400", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 ( GLOBE NEWSWIRE ) -- In a release issued under the same headline earlier today by uniQure N.V. ( NASDAQ: QURE ) , please note that all the numbers have been updated. The corrected release follows: ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.003801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.468029", "ticker_sentiment_score": "0.009244", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2022/06/22/2466978/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20220622T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 ( GLOBE NEWSWIRE ) -- uniQure N.V. ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.002388, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.266391", "ticker_sentiment_score": "0.007599", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.benzinga.com/pressreleases/22/06/g27808639/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4", "time_published": "20220622T110500", "authors": ["Globe Newswire"], "summary": "LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 ( GLOBE NEWSWIRE ) -- uniQure N.V. QURE, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.016148, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.252071", "ticker_sentiment_score": "0.003529", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2022/06/09/uniqure-nasdaqqure-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20220609T021842", "authors": ["admin"], "summary": "uniQure ( NASDAQ:QURE - Get Rating ) was upgraded by StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued on Wednesday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.00937, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.062014", "ticker_sentiment_score": "0.015813", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.062014", "ticker_sentiment_score": "0.015813", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.244354", "ticker_sentiment_score": "0.010525", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.062014", "ticker_sentiment_score": "0.011673", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.062014", "ticker_sentiment_score": "0.003436", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2022/05/11/2440669/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20220511T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, May  11, 2022   ( GLOBE NEWSWIRE )  -- uniQure N.V.  ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a ma", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.001713, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.269033", "ticker_sentiment_score": "0.00576", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.benzinga.com/pressreleases/22/05/g27131298/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4", "time_published": "20220511T110500", "authors": ["Globe Newswire"], "summary": "LEXINGTON, Mass. and AMSTERDAM, May  11, 2022   ( GLOBE NEWSWIRE )  -- uniQure N.V.  ( NASDAQ:QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a mat", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.017656, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.256179", "ticker_sentiment_score": "0.004776", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure  ( NASDAQ:QURE )  Lowered to Sell at StockNews.com", "url": "https://www.defenseworld.net/2022/05/10/uniqure-nasdaqqure-lowered-to-sell-at-stocknews-com.html", "time_published": "20220510T085845", "authors": ["admin"], "summary": "StockNews.com downgraded shares of uniQure  ( NASDAQ:QURE - Get Rating )  from a hold rating to a sell rating in a research report released on Monday morning.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=QURE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.010247, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.056607", "ticker_sentiment_score": "0.016212", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.168687", "ticker_sentiment_score": "0.016025", "ticker_sentiment_label": "Neutral"}, {"ticker": "LFUS", "relevance_score": "0.056607", "ticker_sentiment_score": "0.015813", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHN", "relevance_score": "0.056607", "ticker_sentiment_score": "0.006475", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2022/05/02/2434019/0/en/uniQure-Announces-Multiple-Presentations-at-Upcoming-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html", "time_published": "20220502T204500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, May  02, 2022   ( GLOBE NEWSWIRE )  -- uniQure N.V.  ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be deli", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.007453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.160099", "ticker_sentiment_score": "0.011115", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.080458", "ticker_sentiment_score": "0.001122", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting", "url": "https://www.benzinga.com/pressreleases/22/05/g26948470/uniqure-announces-multiple-presentations-at-upcoming-american-society-of-gene-and-cell-therapy-asg", "time_published": "20220502T204500", "authors": ["Globe Newswire"], "summary": "LEXINGTON, Mass. and AMSTERDAM, May  02, 2022   ( GLOBE NEWSWIRE )  -- uniQure N.V.  ( NASDAQ:QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be deliv", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.021977, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.151682", "ticker_sentiment_score": "0.01345", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.076188", "ticker_sentiment_score": "0.000377", "ticker_sentiment_label": "Neutral"}]}, {"title": "uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress", "url": "https://www.globenewswire.com/news-release/2022/05/02/2433340/0/en/uniQure-Announces-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html", "time_published": "20220502T110500", "authors": ["uniQure Inc."], "summary": "~ Partner CSL Behring submitted Marketing Authorization Application  ( MAA )  in Europe foretranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency  ( EMA ) and granted accelerated assessment ~", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.174975, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.016796", "ticker_sentiment_score": "0.210379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HTGC", "relevance_score": "0.016796", "ticker_sentiment_score": "-0.002722", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.033585", "ticker_sentiment_score": "0.030096", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPZM", "relevance_score": "0.033585", "ticker_sentiment_score": "0.210379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.016796", "ticker_sentiment_score": "0.210379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease", "url": "https://www.globenewswire.com/news-release/2022/03/21/2406555/0/en/uniQure-Announces-Completion-of-Patient-Enrollment-in-the-First-Two-Cohorts-of-its-Phase-I-II-Clinical-Trial-of-AMT-130-for-the-Treatment-of-Huntington-s-Disease.html", "time_published": "20220321T110500", "authors": ["uniQure Inc."], "summary": "LEXINGTON, Mass. and AMSTERDAM, March  21, 2022   ( GLOBE NEWSWIRE )  -- uniQure N.V.  ( NASDAQ: QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its ran", "banner_image": "https://ml.globenewswire.com/Resource/Download/2ba61fe2-12e5-4a01-afe1-419652b31512?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.010346, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.114682", "ticker_sentiment_score": "0.010346", "ticker_sentiment_label": "Neutral"}]}]}